The stock will likely react negatively to the significant EPS miss and lowered revenue guidance, despite maintained EBITDA targets. Monitor pharma marketing trends and AI cost savings execution. The insider buying spree ($28.8M in 30 days) suggests confidence in the long-term thesis, but near-term headwinds are clear.
Price Chart
Executive Summary
Phreesia reported Q4 revenue of $127.1M (16% YoY growth) but missed EPS estimates with $0.02 vs $0.31 expected, driven by higher costs. The company lowered its FY2027 revenue guidance to $510-520M (from $545-559M) due to reduced pharma marketing spend, particularly in vaccines and GLP-1 drugs, but maintained its Adjusted EBITDA guidance of $125-135M through cost efficiencies from AI-driven automation.
Key Financial Metrics
Key Facts
- Q4 revenue: $127.1M (+16% YoY), but EPS of $0.02 missed consensus of $0.31 by 93.5%
- Lowered FY2027 revenue guidance to $510-520M (down $35-49M) due to reduced pharma client spending commitments
- Maintained Adjusted EBITDA guidance of $125-135M despite revenue cut, citing AI-driven efficiency gains
- Network solutions revenue under pressure from vaccine and GLP-1 drug marketing pullbacks
- AccessOne acquisition contributing as expected; refinancing completed with new $275M credit facility
Financial Impact
Revenue guidance reduced by $35-49M; EBITDA margin expansion expected to offset most of the decline
Risk Factors
- Continued weakness in pharma marketing spend could lead to further guidance cuts
- AI-driven cost savings may not materialize as quickly or fully as expected
- Execution risk in integrating AccessOne and scaling ProviderConnect
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001412408-26-000084 |
| Document: phr-20260330.htm | 0001412408-26-000084 |
| Document: 0001412408-26-000084-index-headers.html | 0001412408-26-000084 |
| Document: 0001412408-26-000084-index.html | 0001412408-26-000084 |
| Document: 0001412408-26-000084.txt | 0001412408-26-000084 |
| 8-K Data (Synthetic) | 0001412408-26-000084 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $11.10 $10.07 | ▲ +9.28% | ▲ +8.09% | $10.36 (+6.67%) |
May 14, 2026 20w ago | DEFA14A | $8.77 $9.15 | ▲ +4.33% | ▲ +2.21% | $10.36 (+18.13%) |
Apr 10, 2026 25w ago | Insider Cluster | $8.06 $9.83 | ▼ −21.96% | ▼ −13.43% | $10.36 (−28.54%) |
Apr 10, 2026 25w ago | Insider Cluster | $8.06 $9.83 | ▼ −21.96% | ▼ −13.43% | $10.36 (−28.54%) |
Apr 3, 2026 26w ago | 8-K | $9.15 $9.67 | ▼ −5.68% | ▲ +3.30% | $10.36 (−13.22%) |
Mar 18, 2026 28w ago | Insider Cluster | $11.20 $9.17 | ▼ −18.13% | ▼ −24.17% | $10.36 (−7.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access